uuid:
  -
    value: a703daae-d7a9-4635-ab89-dc0de064f0b5
langcode:
  -
    value: und
type:
  -
    target_id: case_series
    target_type: node_type
    target_uuid: 0ea0fe3a-e616-4d45-88b7-f6bb126fd852
revision_timestamp:
  -
    value: '2016-07-26T19:30:50+00:00'
    format: 'Y-m-d\TH:i:sP'
revision_uid:
  -
    target_type: user
    target_uuid: 7f2b027c-635a-47bd-9500-94902c2d3670
revision_log: {  }
status:
  -
    value: true
uid:
  -
    target_type: user
    target_uuid: 7f2b027c-635a-47bd-9500-94902c2d3670
title:
  -
    value: 'Sanofi-Synthelabo and Aventis: The Birth of a National Champion (A)'
created:
  -
    value: '2016-07-26T19:30:50+00:00'
    format: 'Y-m-d\TH:i:sP'
changed:
  -
    value: '2016-07-26T19:30:50+00:00'
    format: 'Y-m-d\TH:i:sP'
promote:
  -
    value: false
sticky:
  -
    value: false
default_langcode:
  -
    value: true
revision_translation_affected:
  -
    value: true
path:
  -
    alias: /faculty-and-research/case-series/id/a06-05-0014
body:
  -
    value: '<p><span>It was late on Thursday, April 22, 2004, and Jean-Francois Dehecq, the Chief Executive Officer (CEO) of Sanofi-Synthelabo (Sanofi), France''s second largest pharmaceutical company, was sitting in his office thinking about what had happened over the last three months. On January 26, 2004, he had launched a hostile tender offer to acquire Aventis, France''s largest pharmaceutical company. The merger between Sanofi and Aventis would have created the world''s third largest pharmaceutical company, closing the gap with U.S.-based Pfizer and U.K.-based GlaxoSmith-Kline (GSK). Jean-Francois Dehecq had offered ยฃรก48.6 billion, but his offer had been rejected by Aventis''s Supervisory Board. Since the end of January, Aventis had been fighting back, launching a poison pill and inviting Novartis, Switzerland''s largest pharmaceutical company, to act as a white knight.</span></p>'
    format: basic_html
    processed: ''
    summary: ''
    summary_processed: ''
field_case_number:
  -
    value: A06-05-0014
field_case_page_length:
  -
    value: '27 pages'
field_case_series_author:
  - {  }
field_case_series_date: {  }
field_case_series_image: {  }
field_case_series_industry:
  - {  }
field_case_series_year:
  -
    value: '2005-01-01'
field_case_setting:
  -
    value: France
field_case_source:
  -
    value: Library
field_case_subject:
  -
    target_type: taxonomy_term
    target_uuid: 5d6eba99-f8ab-4ad8-88bc-9d20e713d129
field_fields:
  -
    target_type: taxonomy_term
    target_uuid: 05f89050-5790-44f5-a957-f1ec4d2ecee4
field_teaching:
  -
    value: 'This case can be used in a class in corporate finance or in mergers and acquisitions (M&As). It is intended to provide a debate over the following issues: (1) the pros and cons of a merger between Sanofi and Aventis; (2) the French government''s interference with the business world in general and with the merger between Sanofi and Aventis in particular; (3) Aventis''s defense against the hostile tender offer and in the use of a poison pill (the Plavix warrants) and the search for a white knight (Novartis); and (4) Aventis''s valuation with two categories of valuation methods: the discounted cash flows (DCF) method (the weighted average cost of capital (WACC) method), and the comparable method (multiples).'
_content_sync:
  entity_type: node
  entity_dependencies:
    user:
      - user.user.7f2b027c-635a-47bd-9500-94902c2d3670
    taxonomy_term:
      - taxonomy_term.case_series_categories.5d6eba99-f8ab-4ad8-88bc-9d20e713d129
      - taxonomy_term.case_series_fields.05f89050-5790-44f5-a957-f1ec4d2ecee4
